JP2013533227A5 - - Google Patents

Download PDF

Info

Publication number
JP2013533227A5
JP2013533227A5 JP2013513645A JP2013513645A JP2013533227A5 JP 2013533227 A5 JP2013533227 A5 JP 2013533227A5 JP 2013513645 A JP2013513645 A JP 2013513645A JP 2013513645 A JP2013513645 A JP 2013513645A JP 2013533227 A5 JP2013533227 A5 JP 2013533227A5
Authority
JP
Japan
Prior art keywords
ethoxy
fgf21
acetylamino
des181
conh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013513645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533227A (ja
Filing date
Publication date
Priority claimed from PCT/EP2010/057986 external-priority patent/WO2010142665A1/en
Application filed filed Critical
Priority claimed from PCT/EP2011/059273 external-priority patent/WO2011154349A2/en
Publication of JP2013533227A publication Critical patent/JP2013533227A/ja
Publication of JP2013533227A5 publication Critical patent/JP2013533227A5/ja
Withdrawn legal-status Critical Current

Links

JP2013513645A 2010-06-08 2011-06-06 Ｆｇｆ２１類似体および誘導体 Withdrawn JP2013533227A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/EP2010/057986 WO2010142665A1 (en) 2009-06-11 2010-06-08 Glp-1 and fgf21 combinations for treatment of diabetes type 2
EPPCT/EP2010/057986 2010-06-08
CN2010001099 2010-07-21
CN2010/001099 2010-07-21
US37329010P 2010-08-13 2010-08-13
US61/373,290 2010-08-13
PCT/EP2011/059273 WO2011154349A2 (en) 2010-06-08 2011-06-06 Fgf21 analogues and derivatives

Publications (2)

Publication Number Publication Date
JP2013533227A JP2013533227A (ja) 2013-08-22
JP2013533227A5 true JP2013533227A5 (https=) 2014-07-24

Family

ID=49179102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013513645A Withdrawn JP2013533227A (ja) 2010-06-08 2011-06-06 Ｆｇｆ２１類似体および誘導体

Country Status (2)

Country Link
JP (1) JP2013533227A (https=)
WO (1) WO2011154349A2 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
CN105601748B (zh) 2011-07-01 2021-08-27 恩格姆生物制药公司 用于代谢病症和疾病治疗的组合物、应用和方法
TWI513705B (zh) * 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
CA2871656A1 (en) * 2012-06-11 2013-12-19 Eli Lilly And Company Fibroblast growth factor 21 variants
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
ES2915851T3 (es) 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CA2927592C (en) 2013-10-28 2020-08-18 Ngm Biopharmaceuticals, Inc. Fgf-19 variants for treating a fgf-19 dependent cancer or tumor
WO2015103782A1 (en) * 2014-01-13 2015-07-16 Wenzhou Medical College Biological Pharmaceuticals And Nature Products Ltd., Co Fgf21 mutant and conjugate thereof
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
RU2729161C2 (ru) 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
AR103246A1 (es) * 2014-12-23 2017-04-26 Novo Nordiks As Derivados de fgf21 y sus usos
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
EP3442997A2 (en) 2016-04-15 2019-02-20 Indiana University Research & Technology Corporation Fgf21 c-terminal peptide optimization
MX2018014475A (es) * 2016-05-25 2019-05-23 Univ Texas Métodos y composiciones para el tratamiento de trastornos secretorios.
WO2017220706A1 (en) 2016-06-22 2017-12-28 Novo Nordisk A/S Pharmaceutical compositions of fgf21 derivatives and uses thereof
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN108619490A (zh) * 2017-03-22 2018-10-09 天士力医药集团股份有限公司 一种长效化突变的人源成纤维生长因子的新用途
US11560416B2 (en) 2017-04-21 2023-01-24 Yuhan Corporation Method for producing dual function proteins and its derivatives
SG11202001379WA (en) 2017-09-08 2020-03-30 Bristol Myers Squibb Co Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
WO2019123427A1 (en) 2017-12-22 2019-06-27 Novartis Ag Methods of treating metabolic disorders with fgf21 variants
KR20210027426A (ko) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
EP3819307A1 (en) 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
EP4087612A1 (en) 2020-01-08 2022-11-16 Bristol-Myers Squibb Company Fgf-21 conjugate formulations
JP2023538533A (ja) 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
WO2022238510A1 (en) * 2021-05-11 2022-11-17 Cytoki Pharma Aps Therapeutic derivatives of interleukin-22
WO2023035817A1 (zh) 2021-09-08 2023-03-16 北京志道生物科技有限公司 一种fgf21突变蛋白及其应用
CA3258215A1 (en) 2022-06-03 2023-12-07 Boehringer Ingelheim International Gmbh RECOMBINANT EXPRESSION OF THE MYELOID-DERIVED GROWTH FACTOR
WO2025073372A1 (en) 2023-10-05 2025-04-10 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
WO2025120204A1 (en) 2023-12-06 2025-06-12 Boehringer Ingelheim International Gmbh Novel formulation comprising myeloid-derived growth factor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032678A1 (en) 1999-11-05 2001-05-10 Smithkline Beecham Corporation sbgFGF-19a
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
JP2007531715A (ja) 2004-03-17 2007-11-08 イーライ リリー アンド カンパニー グリコール結合ｆｇｆ−２１化合物
EP2194064A1 (en) 2004-05-13 2010-06-09 Eli Lilly & Company FGF-21 fusion proteins
KR100854198B1 (ko) 2004-09-02 2008-08-26 일라이 릴리 앤드 캄파니 섬유아세포 성장 인자 21의 뮤테인
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
US7655627B2 (en) 2004-12-14 2010-02-02 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
US20110034373A1 (en) * 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
WO2009030771A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CA2739615C (en) * 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
CN102361647B (zh) * 2009-01-23 2018-02-16 诺沃-诺迪斯克有限公司 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用
JP2012529463A (ja) * 2009-06-11 2012-11-22 ノヴォ ノルディスク アー／エス ２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ

Similar Documents

Publication Publication Date Title
JP2013533227A5 (https=)
JP2018505146A5 (https=)
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
MX2011007544A (es) Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso.
JP2017500289A5 (https=)
JP2012529463A5 (https=)
HRP20181026T1 (hr) Dugodjelujuće formulacije inzulina
MY174002A (en) Combination theraphy for the treatment of diabetes
UA114700C2 (uk) Тверда фармацевтична форма для перорального застосування та процес її виготовлення
WO2011080102A3 (en) Glp-1 analogues and derivatives
JP2013530974A5 (https=)
WO2009011544A3 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
JP2015513544A5 (https=)
HRP20140480T1 (hr) Pegilirani spojevi inzulina lispro
CY1117576T1 (el) Δινουκλεοτιδικα προφαρμακα
EA201100969A1 (ru) Солевые формы органического соединения
WO2009033793A3 (en) Pentagastrin as a therapeutic agent
WO2009043466A3 (en) Therapeutic use of the peptide gluten exorphin a5
WO2009033718A3 (en) Use of anti -inflammatory peptide 1 as a therapeutic agent
TNSN07447A1 (en) Treatment of liver diseases in which iron plays a role in pathogenesis
RU2016135543A (ru) Новые производные инсулина и их применение в медицине
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
WO2009039985A3 (en) Therapeutic uses of urocortin ii
WO2009046822A3 (en) Use of the peptide ymdgtmsqv as a therapeutic agent
ATE495747T1 (de) Kristalline form des ibandronat-natriums und herstellungsverfahren dafür